|
Indications and Dosage
Subcutaneous
Plaque psoriasis Adult: Moderate to severe cases in patients requiring systemic therapy or phototherapy and have failed to response, or have lost response to other systemic therapies: 210 mg once weekly for 3 doses (week 0, 1, and 2), then every 2 weeks thereafter. Discontinue therapy if no response after 16 weeks.
|
|
Contraindications
Active Crohn’s disease, clinically important active infections (e.g. active tuberculosis). Concomitant use with live vaccines.
|
|
Special Precautions
Patient with history of Crohn’s disease, depression or suicidality, chronic or recurrent infection. Pregnancy and lactation.
|
|
Adverse Reactions
Significant: Suicidal ideation and behaviour, serious infections and fungal infection, cryptococcal meningitis, exacerbation of Crohn’s disease.
Blood and lymphatic system disorders: Neutropenia. Gastrointestinal disorders: Diarrhoea, nausea, oropharyngeal pain. General disorders and admin site conditions: Fatigue. Infections and infestations: Influenza, fungal infections including tinea infections (e.g. tinea pedis, tinea versicolor, tinea cruris), skin and mucosal candidiasis. Injury, poisoning and procedural complications: Injection site reactions (e.g. erythema, pain, pruritus, bruising, haemorrhage). Musculoskeletal and connective tissue disorders: Arthralgia, myalgia. Nervous system disorders: Headache. |
|
Monitoring Parameters
Monitor for signs and symptoms of infections and signs of suicidal ideation or behaviour. Perform TB evaluation prior to initiation of therapy.
|
|
Drug Interactions
May increase serum concentration of midazolam.
Potentially Fatal: May diminish therapeutic and enhance adverse/toxic effects of live vaccines. |
|
Action
Description:
Mechanism of Action: Brodalumab is a recombinant human monoclonal (IgG2) antibody which selectively binds to with high affinity and antagonises the interleukin-17 receptor A (IL-17RA). It blocks the activity with cytokine IL-17RA IL-17A, IL-17F, IL-17A/F heterodimer and IL-25, leading to inhibition of cytokine-induced responses, including release of inflammatory cytokines and chemokines. Pharmacokinetics: Absorption: Bioavailability: Approx 55% (SC). Time to peak plasma concentration: Approx 3 days. Distribution: Crosses placenta, enters breastmilk (small amounts). Volume of distribution: 8.9 ± 9.4 L. Metabolism: Undergoes degradation via catabolic pathways into small peptides and amino acids. |
|
Storage
Store between 2-8°C. Do not freeze. Protect from light. Stable for 14 days at room temperature (≤25°C).
|
|
MIMS Class
|
|
ATC Classification
L04AC12 - brodalumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.
|
|
References
Anon. Brodalumab. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 07/10/2019. Buckingham R (ed). Brodalumab. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 07/10/2019. Joint Formulary Committee. Brodalumab. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 07/10/2019. Siliq (Valeant Pharmaceuticals North America LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 07/10/2019.
|
Sign Out
